设计,合成和抗瘤活性评估新型改性18β-glycyrrhetinate衍生物作为PPARγ激动剂
Hongyan Lin1, Shuaijun Cui1, Xinye Xu1
1School of Pharmacy and School of Biological and Food Engineering, Changzhou University, Changzhou, Jiangsu 213164, China.
Bioorganic chemistry
|February 26, 2025
概括
研究人员开发了新型的18β-甘油酸 (18β-GA) 衍生物,作为癌症治疗的强效PPARγ激动剂. 化合物C1对结肠癌细胞具有强烈的抗增殖作用,毒性降低,需要进一步调查.
科学领域:
- 自然产品 化学 化学
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 18β-甘酸 (18β-GA) 是一种甘衍生物,通过PPARγ激动作用显示出抗瘤的潜力.
- 现有的18β-GA衍生物具有有限的疗效和显著的毒性,阻碍了临床应用.
研究的目的:
- 设计和合成具有增强抗瘤活性和降低毒性的新型18β-GA衍生物.
- 为了确定强大的PPARγ激动剂用于癌症治疗.
主要方法:
- 结构-活动关系 (SAR) 分析,构建一个13440个组合库.
- 在体外查18β-GA衍生物的抗瘤活性对人类癌症细胞系.
- 分子对接,动力学模拟和PPARγ活性测试以阐明作用机制.
主要成果:
- 14种新的18β-GA衍生物被确定具有针对多个癌症细胞系的显著抗增殖活性.
- 化合物C1对HT-29结肠癌细胞表现出优异的活性 (IC50 = 12.25μM),比18β-GA高12倍.
- C1诱导G2/M细胞循环停止,抑制迁移,促进细胞亡,并显示出有利的药物相似性和PPARγ激动性.
结论:
- 新的18β-GA衍生物,特别是C1,是开发有效和低毒性抗癌剂的有希望的候选者.
- C1的机制涉及PPARγ激应,细胞循环停止,迁移抑制和亡诱导.
- 由于其强大的抗瘤活性和类似药物的特性,需要对C1进行进一步的临床前研究.
相关概念视频
Structure-Activity Relationships and Drug Design
483
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
483
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
142
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
142
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
2.5K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
2.5K
Glucagon-like Receptor Agonists
291
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
291
Transducer Mechanism: Nuclear Receptors
1.3K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.3K


